查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2020566

2026-2034年急性骨髓性白血病治療藥物全球市場規模、佔有率、趨勢和成長分析報告

Global Acute Myeloid Leukaemia Therapeutics Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 164 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計急性骨髓性白血病治療市場規模將從 2025 年的 44.7 億美元成長到 2034 年的 113.6 億美元，2026 年至 2034 年的複合年成長率為 10.92%。

隨著全球血液癌症發生率的上升，急性骨髓性白血病（AML）治療的全球市場也不斷擴大。 AML是一種快速進展的癌症，會影響骨髓和血細胞，需要即時進行專業的醫療治療。腫瘤學研究和開發的進步正推動著針對AML患者的新型標靶治療和治療方案的研發。

急性骨髓性白血病（AML）治療市場的主要促進因素之一是癌症研發投入的增加。製藥公司正在開發標靶治療和免疫療法等創新治療方法，以改善治療效果。此外，診斷技術的進步使得白血病能夠更早被發現，從而使醫療專業人員能夠儘早啟動治療。

隨著新的治療方案不斷湧現，急性骨髓性白血病（AML）治療市場預計將持續成長。個人化醫療和精準腫瘤學方法使醫生能夠為每位患者量身定做治療方案。隨著研究的不斷深入，這些創新有望顯著提高存活率和患者預後。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章 全球急性骨髓性白血病治療市場：依疾病分類

  • 市場分析、洞察與預測
  • 髓母細胞白血病
  • 骨髓單核細胞白血病
  • 早幼粒細胞白血病
  • 單核細胞白血病
  • 其他疾病

第5章 全球急性骨髓性白血病治療市場：依療法分類

  • 市場分析、洞察與預測
  • 化療
  • 標靶治療
  • 免疫療法
  • 其他治療方法

第6章 全球急性骨髓性白血病治療市場：依給藥途徑分類

  • 市場分析、洞察與預測
  • 腸外
  • 口服

第7章 全球急性骨髓性白血病治療市場：依最終用途分類

  • 市場分析、洞察與預測
  • 醫院和診所
  • 專業醫療中心
  • 居家醫療環境
  • 門診部

第8章 全球急性骨髓性白血病治療市場：按地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第9章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第10章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Astellas Pharma Inc
    • Bristol-Myers Squibb Company
    • Daiichi Sankyo Company Limited
    • Jazz Pharmaceuticals Plc
    • Novartis AG
    • Otsuka Pharmaceuticals Co. Ltd
    • Pfizer Inc
    • Rigel Pharmaceuticals Inc
    • Merck KGaA
    • Sanofi
簡介目錄
Product Code: VMR112116312

The Acute Myeloid Leukaemia Therapeutics Market size is expected to reach USD 11.36 Billion in 2034 from USD 4.47 Billion (2025) growing at a CAGR of 10.92% during 2026-2034.

The global acute myeloid leukaemia (AML) therapeutics market is expanding due to the increasing incidence of blood cancers worldwide. AML is a rapidly progressing cancer that affects the bone marrow and blood cells, requiring immediate and specialized medical treatment. Advances in oncology research are leading to the development of new targeted therapies and treatment approaches for AML patients.

One of the key drivers of the AML therapeutics market is the growing investment in cancer research and drug development. Pharmaceutical companies are developing innovative therapies such as targeted drugs and immunotherapies to improve treatment outcomes. In addition, improved diagnostic technologies are enabling earlier detection of leukemia, which helps healthcare providers begin treatment sooner.

Looking forward, the AML therapeutics market is expected to witness continued growth as new treatment options become available. Personalized medicine and precision oncology approaches are helping doctors tailor treatments to individual patients. As research continues to advance, these innovations are expected to significantly improve survival rates and patient outcomes.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Disease

  • Myeloblastic Leukemia
  • Myelomonocytic Leukemia
  • Promyelocytic Leukemia
  • Monocytic Leukemia
  • Other Diseases

By Treatment

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Other Treatments

By Route of Administration

  • Parenteral
  • Oral

By End Use

  • Hospitals And Clinics
  • Specialty Centers
  • Homecare Setting
  • Ambulatory Care Centers

COMPANIES PROFILED

  • Astellas Pharma Inc, BristolMyers Squibb Company, Daiichi Sankyo Company Limited, Jazz Pharmaceuticals plc, Novartis AG, Otsuka Pharmaceuticals Co Ltd, Pfizer Inc, Rigel Pharmaceuticals Inc, Merck KGaA, Sanofi
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL ACUTE MYELOID LEUKAEMIA THERAPEUTICS MARKET: BY DISEASE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Disease
  • 4.2. Myeloblastic Leukemia Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Myelomonocytic Leukemia Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Promyelocytic Leukemia Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Monocytic Leukemia Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.6. Other Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ACUTE MYELOID LEUKAEMIA THERAPEUTICS MARKET: BY TREATMENT 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Treatment
  • 5.2. Chemotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Targeted Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Immunotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Other Treatments Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ACUTE MYELOID LEUKAEMIA THERAPEUTICS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Route Of Administration
  • 6.2. Parenteral Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ACUTE MYELOID LEUKAEMIA THERAPEUTICS MARKET: BY END USE 2022-2034 (USD MN)

  • 7.1. Market Analysis, Insights and Forecast End Use
  • 7.2. Hospitals And Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.3. Specialty Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.4. Homecare Setting Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.5. Ambulatory Care Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL ACUTE MYELOID LEUKAEMIA THERAPEUTICS MARKET: BY REGION 2022-2034 (USD MN)

  • 8.1. Regional Outlook
  • 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.2.1 By Disease
    • 8.2.2 By Treatment
    • 8.2.3 By Route Of Administration
    • 8.2.4 By End Use
    • 8.2.5 United States
    • 8.2.6 Canada
    • 8.2.7 Mexico
  • 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.3.1 By Disease
    • 8.3.2 By Treatment
    • 8.3.3 By Route Of Administration
    • 8.3.4 By End Use
    • 8.3.5 United Kingdom
    • 8.3.6 France
    • 8.3.7 Germany
    • 8.3.8 Italy
    • 8.3.9 Russia
    • 8.3.10 Rest Of Europe
  • 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.4.1 By Disease
    • 8.4.2 By Treatment
    • 8.4.3 By Route Of Administration
    • 8.4.4 By End Use
    • 8.4.5 India
    • 8.4.6 Japan
    • 8.4.7 South Korea
    • 8.4.8 Australia
    • 8.4.9 South East Asia
    • 8.4.10 Rest Of Asia Pacific
  • 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.5.1 By Disease
    • 8.5.2 By Treatment
    • 8.5.3 By Route Of Administration
    • 8.5.4 By End Use
    • 8.5.5 Brazil
    • 8.5.6 Argentina
    • 8.5.7 Peru
    • 8.5.8 Chile
    • 8.5.9 Rest of Latin America
  • 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.6.1 By Disease
    • 8.6.2 By Treatment
    • 8.6.3 By Route Of Administration
    • 8.6.4 By End Use
    • 8.6.5 Saudi Arabia
    • 8.6.6 UAE
    • 8.6.7 Israel
    • 8.6.8 South Africa
    • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

  • 9.1. Recent Developments
  • 9.2. Company Categorization
  • 9.3. Supply Chain & Channel Partners (based on availability)
  • 9.4. Market Share & Positioning Analysis (based on availability)
  • 9.5. Vendor Landscape (based on availability)
  • 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL ACUTE MYELOID LEUKAEMIA THERAPEUTICS INDUSTRY

  • 10.1. Top Companies Market Share Analysis
  • 10.2. Company Profiles
    • 10.2.1 Astellas Pharma Inc
    • 10.2.2 Bristol-Myers Squibb Company
    • 10.2.3 Daiichi Sankyo Company Limited
    • 10.2.4 Jazz Pharmaceuticals Plc
    • 10.2.5 Novartis AG
    • 10.2.6 Otsuka Pharmaceuticals Co. Ltd
    • 10.2.7 Pfizer Inc
    • 10.2.8 Rigel Pharmaceuticals Inc
    • 10.2.9 Merck KGaA
    • 10.2.10 Sanofi